Key Highlights

  • Champions Oncology reported first quarter Revenue of 15.2 million dollars, beating the 15 million dollar estimate by about 1.24 percent.
  • Adjusted Earnings Per Share came in well above the breakeven estimate, marking a beat of over 600 percent on a small base.
  • Gross Margin improved to 51 percent from 43 percent a year earlier, driven by lower third party radiolabeling costs.
  • Adjusted EBITDA reached approximately 700,000 dollars, the company's fifth consecutive quarter of positive adjusted EBITDA.

An Investment Year Begins to Show Returns

Champions Oncology Inc (NASDAQ:CSBR), a technology enabled oncology research organization, reported first quarter fiscal 2027 revenue of 15.2 million dollars, up approximately 9 percent from 14 million dollars a year earlier and modestly ahead of the 15 million dollar analyst estimate. Chief Executive Officer Rob Brainin characterized the quarter as early evidence that investments made during what the company called an investment year in fiscal 2026 are beginning to pay off.

The company's translational oncology services business, which uses patient derived tumor models to predict how therapies will behave in patients, generated 14.3 million dollars of revenue, with margins holding at improved levels despite the added scale. Data licensing revenue reached 893,000 dollars for the quarter, already exceeding the total data revenue generated across all of fiscal 2026.

Margin Expansion Reflects Operating Leverage

Gross margin for the oncology services Business improved to 51 percent from 43 percent a year earlier, driven primarily by a reduction in third party radiolabeling costs as the company brought more of that capability in house. This margin improvement, combined with revenue growth, helped drive adjusted EBITDA to approximately 700,000 dollars, marking the fifth consecutive quarter of positive adjusted EBITDA for the company.

Sales and Marketing expense rose to 3 million dollars from 1.8 million dollars a year earlier, reflecting a deliberate investment made in the prior year to expand the company's commercial organization across both its research services and data businesses. Management indicated the focus going forward is on generating greater revenue and profitability from this expanded commercial capacity rather than continuing to grow the expense base at a similar pace.

Data Licensing and Corellia Present Long Term Catalysts

Continued growth in data licensing revenue could become an increasingly important contributor over time, as management noted that sponsors leaning on artificial intelligence for Drug Development decisions are increasingly constrained by the availability of deeply characterized, clinically annotated patient derived data, an area where Champions Oncology has built meaningful scale. Progress in strengthening customer relationships within the core translational oncology services business also appears to be supporting more consistent revenue conversion.

The company's wholly owned therapeutic subsidiary, Corellia, remains in active discussions with venture groups and potential pharmaceutical partners regarding funding or licensing arrangements, though management has declined to provide a specific timeline for any outcome. Should Corellia secure external funding or a partnership, management indicated the Capital currently invested in that business would be redirected toward data initiatives and overall profitability, which could accelerate the company's broader financial improvement.

Investment Takeaway

Champions Oncology's first quarter results offer an encouraging data point following what management described as an investment year in fiscal 2026, with revenue growth, margin improvement, and a fifth consecutive quarter of positive adjusted EBITDA all pointing toward improving operating leverage. Whether this trajectory continues may depend on sustained growth in data licensing revenue, which remains inherently lumpy given contract timing, and on progress in securing external funding or partnerships for the Corellia therapeutic subsidiary. Management has signaled it intends to report against this same framework throughout fiscal 2027.